Raven and Emory University Sign Cancer Stem Cell Collaboration
Posted on: Tuesday, 4 March 2008, 06:00 CST
Raven biotechnologies has entered into a research collaboration with Leland Chung, director of the Molecular Urology and Therapeutics Program at the Emory University Medical School's Department of Urology.
Under the terms of the collaboration, Raven will provide Emory with access to its prostate cancer stem cells. Raven will also provide Emory with a library of antibodies targeting cancer stem cells to study their use as potential diagnostic tools for cancer prognosis and treatment. Using Raven's unique prostate cancer derived cancer stem cells (CSCs), Raven and Emory will collaboratively examine prostate cancer biology, disease progression and subsequent metastasis.
George Schreiner, CEO of Raven biotechnologies, said: "We are excited about our collaboration with Emory University because of their work in cancer stem cells that compliments Raven's expertise in this area, as well as their multidisciplinary approach to cancer research and clinical applications."
Source: Datamonitor
Related Articles
- Gene 'Cancer-Proofs' Rodent's Cells
- Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
- Discovery Pinpoints New Link Between Cancer Cells, Stem Cells
- Raven and CMC Icos Collaborate in Cancer Drug Development
- View Details on the Top 20 Companies With Products in the Early Stage of Development for Non-Small-Cell Lung Cancer, Lung Cancer or Small Cell Lung Cancer
- NovaThera and Gamida Cell Announce a Collaboration Agreement to Develop Cell Therapeutics for Lung Disease
- Integrated BioPharma and City of Hope Cancer Center Announce Clinical Trial Collaboration to Lower Side Effects of Chemotherapy Drugs
- Rapid restoration of immunity in immune-suppressed cancer patients using T-cell vaccines
- Cholesterol Targeting Alters Lipid Raft Composition and Cell Survival in Prostate Cancer Cells and Xenografts
- Internalization of Luminescent Calcium Phosphate Nanoparticles By Human Cancerous Pancreatic Ductal Cells (Capan-1 Line)
 |
 |
User Comments (0)
RSS Feeds